Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Incyte Corp INCY

Healthcare Biotechnology
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts clinical development and commercial operations from its European headquarters in Morges, Switzerland and its other offices across Europe, as well as its Japanese office in Tokyo and its Canadian headquarters in Montreal. It operates... see more

Recent & Breaking News (NDAQ:INCY)

Incyte Announces Positive Top-Line Results from Phase III Study of Ruxolitinib in Patients with Polycythemia Vera

Business Wire March 7, 2014

Catalysts Drive These Stocks: Mara Goldstein

Equities.com February 21, 2014

Incyte to Present at Upcoming Investor Conferences

Business Wire February 18, 2014

Incyte Reports 2013 Fourth-Quarter and Year-End Financial Results; Provides 2014 Financial Guidance; Updates Shareholders on Key Clinical Programs

Business Wire February 12, 2014

Incyte Announces Clinical Trial Collaboration with Merck to Evaluate Combination of Two Novel Immunotherapies

Business Wire February 5, 2014

Incyte to Report Fourth Quarter/Year-End 2013 Financial Results on February 12

Business Wire January 27, 2014

Incyte Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Business Wire January 14, 2014

Incyte Names Hervé Hoppenot President and Chief Executive Officer

Business Wire January 13, 2014

Incyte to Present at the 32nd Annual J. P. Morgan Healthcare Conference

Business Wire December 18, 2013

Quarterly Changes to the NASDAQ OMX Q-50 Index

Globe Newswire December 16, 2013

Positive Results Presented from Proof-of-Concept Phase II Clinical Trial of Incyte's Oral JAK1 Inhibitor in Patients with Myelofibrosis

Business Wire December 9, 2013

Jakafi® (ruxolitinib) Continues to Show Improved Overall Survival for Patients with Myelofibrosis in Further Analyses of Phase III Data Presented at 2013 ASH

Business Wire December 9, 2013

Incyte Completes Offering of $750 Million of Convertible Senior Notes

Business Wire November 14, 2013

Incyte Prices Offering of $700 Million of Convertible Senior Notes

Business Wire November 7, 2013

Incyte Reports Third-Quarter 2013 Financial Results; Updates Shareholders on Key Clinical Programs

Business Wire October 31, 2013

Positive Results Presented from Proof-of-Concept Phase II Clinical Trial of Incyte's Oral JAK1 Inhibitor in Patients with Active Rheumatoid Arthritis

Business Wire October 28, 2013

Incyte to Report Third Quarter 2013 Financial Results on October 31

Business Wire October 10, 2013

Positive Results Presented from Proof-of-Concept Phase II Clinical Trial of Incyte's Oral JAK1 Inhibitor in Patients with Chronic Plaque Psoriasis

Business Wire October 3, 2013

Wall Street Fundamentals Releases New In-Depth Stock Reports on BCRX, INCY, LXRX and SNSS

Accesswire September 27, 2013

Incyte to Ring NASDAQ Stock Market Opening Bell in Support of Blood Cancer Awareness Month

Business Wire September 3, 2013